CVD represents one of the leading causes of morbidity worldwide, with heart disease, stroke and hypertension ranking among the top causes of morbidity in the USA.1 Many patients with established CVD remain at risk for subsequent ischemic events.2
Patients with a history of prior ischemic events are at higher risk of experiencing subsequent CV events, especially within the first year of the index event.2
Even patients who are event-free in the year following the index event remain at significant risk for future events, with event rates after MI increasing even years after the index event.3-6
Reach Registry: international, observational, prospective cohort of 68,236 patients at risk for atherothrombotic events. 45,227 patients from 29 countries in the REACH registry
completed the 4-year analysis. 77% of the patients in this group were on ≥ 1 lipid-lowering drug.
CV, cardiovascular; MI, myocardial infarction.
Events were defined as stroke, cardiovascular death, polyvascular disease, or cardiovascular hospitalization.
Studies show that despite optimal treatment with lipid-lowering agents including statins, niacin and fibrates, significant residual CV risk remains regardless of dose and treatment setting.1
CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol.
Landmark statin trials demonstrated that while further reductions in LDL-C, following high-intensity lipid-lowering treatment, are associated with additional reductions in CV risk in patients with established CVD, even those achieving LDL-C levels 62–81 mg/dL remain at risk for future events.1-5
*Mean or median LDL-C after treatment.
CV, cardiovascular; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol.